ACT Brief: Real-World Data Access, eSource Implementation Progress, and FDA Regulatory Trends
ACT Brief: Real-World Data Access Expansion, eSource Implementation at Scale, and FDA ...
Summary
This brief reports on Thermo Fisher's expanded real-world data (RWD) access through a partnership with HealthVerity, the progress of FHIR standard-based eSource implementation, and regulatory challenges faced by Replimune regarding its oncolytic immunotherapy.
Details
The ACT Brief examines key trends shaping clinical operations and drug development. First, Thermo Fisher entered a strategic collaboration with HealthVerity to gain enterprise-level access to claims data covering over 270 million de-identified patient lives. This partnership integrates taXonomy claims data with over 70 curated datasets to improve site selection precision, accelerate study startup, and strengthen AI-driven analytics for real-world evidence (RWE) generation. Second, an interview with Veeva Systems' Nick Frenzer highlighted that eSource implementation is becoming more efficient using FHIR-based API standards and a site-owned platform approach. This significantly reduces integration work from hundreds of hours to fewer than ten hours, allowing staff to focus on patients rather than data entry. Finally, Replimune received a second FDA complete response letter for RP1 in combination with nivolumab for advanced melanoma, despite prior breakthrough designation and positive Phase II data. The company raised concerns about regulatory inconsistency, underscoring the complexity of drug approval processes. These developments highlight advancements in clinical trial efficiency and regulatory hurdles.
Original content copyright by respective publishers